Filing Details
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on October 27, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:NAUT
Nautilus Biotechnology, Inc. (NAUT) Files Quarterly Report for Q0
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on October 27, 2026.
At publication ·
What changed
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Nautilus Biotechnology filed its Q0 quarterly report (Form 10-Q) with the SEC on October 27, 2026.
- The company's stock trades at $2.89 with a market capitalization of $250.7 million.
- The 10-Q filing contains unaudited financial statements and management commentary on business performance and emerging trends.
Market Context
Nautilus Biotechnology, Inc.'s stock currently trades at $2.89 with a market capitalization of $250.7M.
The 10-Q provides Nautilus Biotechnology, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Nautilus Biotechnology, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View NAUT Stock Page
Frequently Asked Questions
Where can I read NAUT's SEC filings?
Browse all filings on our NAUT SEC filings page.
What types of SEC filings does Nautilus Biotechnology, Inc. file?
Public companies like Nautilus Biotechnology, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.